Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinghua Weikangjiao Pill for prevention of antiplatelet drug-induced gastric and small intestinal mucosal injury
ChiCTR2000030063Phase 4Not yet recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Mar 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of jinghuaweikang in gastric mucosal injury and Small intestinal mucosal injury (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Capsule endoscopy score. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
jinghuaweikang
03
Conditions
gastric mucosal injurySmall intestinal mucosal injury
Beyond the preview
Go deeper on ChiCTR2000030063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030063.